陇神戎发：控股子公司获得药物临床试验补充申请批准通知书

Core Viewpoint - The company, Longshen Rongfa, announced that its subsidiary, Gansu Puan Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for two supplementary applications for clinical trials of the drug Brivaracetam oral film, which is intended for the treatment of schizophrenia [1] Group 1 - The approval includes the addition of two new specifications: 0.5mg and 1mg [1] - The supplementary application was accepted on May 20 and meets the requirements for drug registration [1] - The clinical trials for Brivaracetam oral film can continue as per the approved content [1]